Clinical Trial Update: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for PEN-221 in somatostatin receptor 2 expressing advanced cancers, including neuroendocrine tumors and small cell lung cancer. Results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumors
• Small Cell Lung Cancer

Drugs mentioned

• PEN-221 (not specified)

Snippet

Sponsor: Tarveda Therapeutics | Conditions: Neuroendocrine Tumors, Carcinoma, Small Cell Lung | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-12-14